CAR T-cell Therapy in Lymphocytic Leukemia| A Pipeline Analysis Report 2018| Technavio

July 5, 2018

Technavio has published a new report on the drug development pipeline for CAR T-cell therapy in lymphocytic leukemia, including a detailed study of the pipeline molecules. (Graphic: Business Wire)

LONDON--(BUSINESS WIRE)--Jul 5, 2018--Technavio has announced their latest pipeline analysis report on the market. The report includes a detailed analysis of the pipeline molecules under investigation within the defined data collection period to treat CAR T-cell therapy in lymphocytic leukemia.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180705005430/en/

Technavio has published a new report on the drug development pipeline for CAR T-cell therapy in lymphocytic leukemia, including a detailed study of the pipeline molecules. (Graphic: Business Wire)

This report by presents a detailed analysis of the market, including regulatory framework, drug development strategies, recruitment strategies, and key companies that are expected to play an essential role in the growth of the market in the near future.

This report is available at a USD 1,000 discount for a limited time only:

CAR T-cell therapy in lymphocytic leukemia: Market overview

Leukemia is the cancer of blood cells. In leukemia, the damaged cells do not die at the same rate as the normal cells. It causes the accumulation of damaged cells, thus reducing the space for the normal cells to function and survive.

According to a senior analyst at Technavio for research on oncology , “Lymphocytic leukemia is the cancer that starts during the early formation time of the lymphocytes in the bone marrow. It is categorized into chronic lymphocytic leukemia and acute lymphocytic leukemia.”

CAR T-cell therapy in lymphocytic leukemia: Segmentation analysis

This market research report segments the market based on therapies employed that includes monotherapy and monotherapy+combination therapy, RoA (intravenous and undisclosed), therapeutic modalities (cell), targets for drugs under development (CD19, CD22, CD33, CD7, CD123, and CD19 and CD22), drugs under development (pre-clinical, phase I, phase I/II, phase II, and phase III), and recruitment status (recruiting, not yet recruiting, completed, NA, and unknown). It provides an in-depth analysis of the prominent factors influencing the market, including drivers, opportunities, trends, and industry-specific challenges.

Looking for more information on this market?

Technavio’s sample reports are free of charge and contain multiple sections of the report such as the market size and forecast, drivers, challenges, trends, and more.

Some of the key topics covered in the report include:

Scope of the Report

Regulatory Framework

Drug Development Landscape

Drugs under development Indications coverage

Drug Development Strategies

Therapies employed RoA Therapeutic modality Geographical coverage

Recruitment Strategies

Recruitment status Gender Age Recruitment volume

Key Companies

Type of players Company Overview

Discontinued or Dormant Molecules

About Technavio

is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

If you are interested in more information, please contact our media team at .

View source version on businesswire.com:https://www.businesswire.com/news/home/20180705005430/en/

CONTACT: Technavio Research

Jesse Maida

Media & Marketing Executive

US: +1 844 364 1100

UK: +44 203 893 3200




SOURCE: Technavio Research

Copyright Business Wire 2018.

PUB: 07/05/2018 12:23 PM/DISC: 07/05/2018 12:23 PM


Update hourly